NCT02844790View on ClinicalTrials.gov

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 26, 2016

Primary Completion Date

September 26, 2016

Study Completion Date

September 27, 2016

Conditions

Healthy

Interventions

DRUG

insulin degludec/insulin aspart

A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).

Trial Locations (1)

100730

Novo Nordisk Investigational Site, Beijing

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY